These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 38169605)
1. Generic design principles for antibody-based tumour necrosis factor (TNF) receptor 2 (TNFR2) agonists with FcγR-independent agonism. Anany MA; Haack S; Lang I; Dahlhoff J; Vargas JG; Steinfatt T; Päckert L; Weisenberger D; Zaitseva O; Medler J; Kucka K; Zhang T; Van Belle T; van Rompaey L; Beilhack A; Wajant H Theranostics; 2024; 14(2):496-509. PubMed ID: 38169605 [No Abstract] [Full Text] [Related]
2. Antagonistic Antibody Targeting TNFR2 Inhibits Regulatory T Cell Function to Promote Anti-Tumor Activity. Chen Y; Jia M; Wang S; Xu S; He N Front Immunol; 2022; 13():835690. PubMed ID: 35251028 [TBL] [Abstract][Full Text] [Related]
3. The Significance of Tumor Necrosis Factor Receptor Type II in CD8 Ye LL; Wei XS; Zhang M; Niu YR; Zhou Q Front Immunol; 2018; 9():583. PubMed ID: 29623079 [TBL] [Abstract][Full Text] [Related]
4. Antibody-based soluble and membrane-bound TWEAK mimicking agonists with FcγR-independent activity. Zaitseva O; Hoffmann A; Löst M; Anany MA; Zhang T; Kucka K; Wiegering A; Otto C; Wajant H Front Immunol; 2023; 14():1194610. PubMed ID: 37545514 [TBL] [Abstract][Full Text] [Related]
5. Modulation of Regulatory T Cell Activity by TNF Receptor Type II-Targeting Pharmacological Agents. Zou H; Li R; Hu H; Hu Y; Chen X Front Immunol; 2018; 9():594. PubMed ID: 29632537 [TBL] [Abstract][Full Text] [Related]
6. Intrinsic TNF/TNFR2 interactions fine-tune the CD8 T cell response to respiratory influenza virus infection in mice. Wortzman ME; Lin GH; Watts TH PLoS One; 2013; 8(7):e68911. PubMed ID: 23874808 [TBL] [Abstract][Full Text] [Related]
7. TNFR1 delivers pro-survival signals that are required for limiting TNFR2-dependent activation-induced cell death (AICD) in CD8+ T cells. Twu YC; Gold MR; Teh HS Eur J Immunol; 2011 Feb; 41(2):335-44. PubMed ID: 21268004 [TBL] [Abstract][Full Text] [Related]
8. Phenotypic screening reveals TNFR2 as a promising target for cancer immunotherapy. Williams GS; Mistry B; Guillard S; Ulrichsen JC; Sandercock AM; Wang J; González-Muñoz A; Parmentier J; Black C; Soden J; Freeth J; Jovanović J; Leyland R; Al-Lamki RS; Leishman AJ; Rust SJ; Stewart R; Jermutus L; Bradley JR; Bedian V; Valge-Archer V; Minter R; Wilkinson RW Oncotarget; 2016 Oct; 7(42):68278-68291. PubMed ID: 27626702 [TBL] [Abstract][Full Text] [Related]
9. An immunocytokine consisting of a TNFR2 agonist and TNFR2 scFv enhances the expansion of regulatory T cells through TNFR2 clustering. Inoue M; Tsuji Y; Kashiwada A; Yokoyama A; Iwata A; Abe Y; Kamada H; Tsunoda SI Biochem Biophys Res Commun; 2024 Feb; 697():149498. PubMed ID: 38262291 [TBL] [Abstract][Full Text] [Related]
10. Scutellarin enhances anti-tumor immune responses by reducing TNFR2-expressing CD4 Chen S; Li R; Chen Y; Chou CK; Zhang Z; Yang Y; Liao P; Wang Q; Chen X Biomed Pharmacother; 2022 Jul; 151():113187. PubMed ID: 35676787 [TBL] [Abstract][Full Text] [Related]
11. Increased Regulatory T Cells in Peripheral Blood of Acute Myeloid Leukemia Patients Rely on Tumor Necrosis Factor (TNF)-α-TNF Receptor-2 Pathway. Wang M; Zhang C; Tian T; Zhang T; Wang R; Han F; Zhong C; Hua M; Ma D Front Immunol; 2018; 9():1274. PubMed ID: 29922294 [TBL] [Abstract][Full Text] [Related]
16. Antibody-mediated targeting of TNFR2 activates CD8 Tam EM; Fulton RB; Sampson JF; Muda M; Camblin A; Richards J; Koshkaryev A; Tang J; Kurella V; Jiao Y; Xu L; Zhang K; Kohli N; Luus L; Hutto E; Kumar S; Lulo J; Paragas V; Wong C; Suchy J; Grabow S; Dugast AS; Zhang H; Depis F; Feau S; Jakubowski A; Qiao W; Craig G; Razlog M; Qiu J; Zhou Y; Marks JD; Croft M; Drummond DC; Raue A Sci Transl Med; 2019 Oct; 11(512):. PubMed ID: 31578241 [TBL] [Abstract][Full Text] [Related]
17. Generation and characterization of novel co-stimulatory anti-mouse TNFR2 antibodies. Segués A; van Duijnhoven SMJ; Parade M; Driessen L; Vukovic N; Zaiss D; Sijts AJAM; Berraondo P; van Elsas A J Immunol Methods; 2021 Dec; 499():113173. PubMed ID: 34699840 [TBL] [Abstract][Full Text] [Related]
18. HERA-GITRL activates T cells and promotes anti-tumor efficacy independent of FcγR-binding functionality. Richards DM; Marschall V; Billian-Frey K; Heinonen K; Merz C; Redondo Müller M; Sefrin JP; Schröder M; Sykora J; Fricke H; Hill O; Gieffers C; Thiemann M J Immunother Cancer; 2019 Jul; 7(1):191. PubMed ID: 31324216 [TBL] [Abstract][Full Text] [Related]
19. Progranulin promotes tumour necrosis factor-induced proliferation of suppressive mouse CD4⁺ Foxp3⁺ regulatory T cells. Hu Y; Xiao H; Shi T; Oppenheim JJ; Chen X Immunology; 2014 Jun; 142(2):193-201. PubMed ID: 24383743 [TBL] [Abstract][Full Text] [Related]
20. Tumor Necrosis Factor Receptor 2 Restricts the Pathogenicity of CD8(+) T Cells in Mice With Colitis. Punit S; Dubé PE; Liu CY; Girish N; Washington MK; Polk DB Gastroenterology; 2015 Oct; 149(4):993-1005.e2. PubMed ID: 26072395 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]